ABSTRACT On the basis of theoretical considerations, a peptide (H Discovery of hepatitis virus-specific antigens (1-3) and their association with the outer membrane ofhepatitis B virus (HBV) (4, 5) has led to rapid advances in the prevention of HBV infection. This has been achieved through detection of HBV carrier blood donors by testing for the HBV surface antigen (HBsAg) (6, 7), and by passive (8-12) and active (13-18) immunization.
munization.
The protective effect of hepatitis B immune globulin, prepared from plasma selected for high anti-HBsAg content, as well as the demonstration that protective immunity can be induced, albeit at high cost, by the purified 23,000-dalton HBsAg polypeptide isolated from HBV-associated subviral particles (19) , has suggested that anti-HBsAg is a protective antibody. Other surface specificities on the HBV virion could also play a similar role (18, 20) .
HBsAg also exhibits generally mutually exclusive strain-specific subtype antigenic determinants-e.g., d/y (21) and w/r (22)-in addition to the determinant a common to all strains. Available evidence suggests that the subtype specificities play no role in providing protective immunity (23, 24) , and thus that HBsAg/a may be the critical determinant.
It is thus ofobvious interest to learn the amino acid sequence of the antibody-combining site, or epitope, of HBsAg/a. Progress towards this goal has depended on two key advances: isolation and characterization of HBV DNA (25) and determination of its sequence through recombinant DNA methods (26) (27) (28) (29) . This permitted prediction of the amino acid sequence of the product of the HBsAg gene (the s gene) (30, 31) . Using a theoretical model, Hopp and Woods (32) For immunization it was necessary to remove the peptide from the polystyrene beads with hydrofluoric acid (34). The isolated polypeptide was then attached to aldehyde-stabilized human erythrocytes (35) , or polymerized with 2.5% (vol/vol) glutaraldehyde in 0.01 M sodium phosphate buffer (pH 7.2)/ 0.15 M NaCl for 1 hr at room temperature and overnight at 4°C. The polymerized preparation was passed through a Sephadex G-200 column and the void volume fraction was recovered.
Passive Hemagglutination and Hemagglutination Inhibition. These tests were carried out as described (36) , except that HBsAg/ay cells were obtained from Electronucleonics Laboratories (Bethesda, MD). In addition, some experiments utilized aldehyde-stabilized human group 0 erythrocytes covalently coated with HBsAg/ad (36) or with human serum albumin. Monospecific antibody reagents were prepared as described (36) . Anti-HBsAg/a is abbreviated anti-HBs/a, etc.
Immunization of Mice. Female Swiss ICR strain mice, weighing 20-25 g, were immunized as described. The publication costs ofthis article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact.
Proc. NatL Acad. Sci. USA 79 (1982) Anti-HBsAg Quantitation by Solid-Phase Radioimmunoassay. Anti-HBsAg was also quantitated with a parallel line assay (18) ticular sequence of amino acids, most probably including the sequence Lys-Pro-Thr-Asp-Gly-Asn.
Recently, Vyas (37) reported that a synthetic peptide, beginning at position 134 in the s protein sequence, had HBsAg activity demonstrable by hemagglutination inhibition against antiHBs. The subtype composition of the antiserum, or epitope(s) was not reported. Lerner and his colleagues (38) have also synthesized immunogenic peptides based on the sequence of HBsAg (38) . Seven of 13 peptides synthesized elicited antibody with the peptides used for immunization, and four ofthese antisera reacted also with native HBsAg polypeptides. It is unclear why their peptide corresponding to portions 140-148, which includes the H epitope region, was only marginally immunogenic.
The limited adsorbtive capacity of H peptide-coated ,beads-i.e., 1 mIU of anti-HBsAg adsorbed per 10 mg of peptide-suggests that the peptide as presently constituted does not closely mimic the tertiary structure of the native epitope. This is not surprising, because the native sequence contains cysteine groups on either side ofthe epitope: positions 137, 138, 139, 147, and 149. These probably form disulfide bridges, one of which may circularize the region containing the epitope. Reduction largely destroys HBsAg activity (39) , which suggests that a disulfide-bonded loop configuration is vital to full antigenic activity in this region. Synthesis of analogues containing cysteine residues will allow testing of the immunological consequences of loop closure in this peptide.
Effective vaccines for prevention of HBV infections are now available (14) (15) (16) (17) , and others are contemplated or under development. These include vaccines derived from viral components circulating in the blood ofchronic carriers (14) (15) (16) (17) as well as the possible use of HBsAg expressed in prokaryotes such as Escherichia coli (40) , in eukaryotic cells such as mouse (41) or human (42) cells in cell culture, or even in human HBsAgsecreting hepatocellular carcinoma cells (43) . Vaccines have been proposed that would contain all membranous components ofthe virion or its subviral particles (18) , isolated 20-nm subviral membrane particles (14) (15) (16) (17) , isolated polypeptides from the subviral particles (19) , micellar aggregates ofsuch isolated polypeptides (43) , and isolated polypeptide fragments attached to suitable carriers (44) .
Almost all of the above approaches suffer from two possible disadvantages, one theoretical, the other practical. Such vaccines could contain unwanted antigenic components, derived from elsewhere in the virion or its associated particles, or from the host cells in which these were synthesized. It is difficult, ifnot impossible, to remove all detectable host components-e.g., human serum albumin, IgG, and some other serum proteins-from even the most highly purified HBsAg particles (45) (46) (47) (48) . Indeed, when such particles derive from HBV e antigen-positive donors, they adsorb efficiently to aggregated human serum albumin (48) . The possibility that such host components, if present in a vaccine including adjuvant might give rise to autoimmune complications has been raised (49) and sought for but so far not found (50) (51) (52) (53) (54) . This is then still only a theoretical danger; on the basis of experience with previous far less pure vaccines, it is probably not of major significance.
The second disadvantage of most presently contemplated HBV vaccines is the high cost. Expensive vaccines cannot be afforded in most regions of the world in the foreseeable future.
A small peptide can be inexpensively and rapidly synthesized in large quantities. For example, 500 mg of H peptide was synthesized by one of us in about a week. Thus a practical solution to the problem of world-wide mass immunization against HBV may be at hand. Important model precedents for this approach are available (55, 56) .
Erythrocytes were used as a convenient carrier for immunization in this study. We recognize that these would not provide a suitable carrier for use in vaccines, and it is necessary to find a more practical carrier.
